ACADIA Pharmaceuticals (NASDAQ:ACAD) EVP Mark Schneyer Sells 5,849 Shares

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) EVP Mark Schneyer sold 5,849 shares of the business’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $29.00, for a total transaction of $169,621.00. Following the completion of the transaction, the executive vice president directly owned 67,828 shares in the company, valued at $1,967,012. This trade represents a 7.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ACADIA Pharmaceuticals Stock Performance

Shares of ACAD stock opened at $29.21 on Friday. The firm has a market cap of $5.03 billion, a price-to-earnings ratio of 13.16, a P/E/G ratio of 16.74 and a beta of 0.81. ACADIA Pharmaceuticals Inc. has a 52 week low of $19.69 and a 52 week high of $29.48. The firm’s 50-day simple moving average is $24.39 and its two-hundred day simple moving average is $23.27.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.11. The company had revenue of $308.00 million during the quarter, compared to analyst estimates of $296.55 million. ACADIA Pharmaceuticals had a net margin of 33.42% and a return on equity of 9.03%. ACADIA Pharmaceuticals’s quarterly revenue was up 16.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.16 EPS. Analysts forecast that ACADIA Pharmaceuticals Inc. will post 0.46 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Citigroup reiterated a “market outperform” rating on shares of ACADIA Pharmaceuticals in a research report on Wednesday. Royal Bank Of Canada boosted their price objective on shares of ACADIA Pharmaceuticals from $36.00 to $37.00 and gave the company an “outperform” rating in a research note on Wednesday. Citizens Jmp upped their target price on shares of ACADIA Pharmaceuticals from $35.00 to $36.00 and gave the stock a “market outperform” rating in a report on Wednesday. Wall Street Zen upgraded shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of ACADIA Pharmaceuticals in a research note on Wednesday, July 29th. Fourteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $33.44.

Key Stories Impacting ACADIA Pharmaceuticals

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its long-term earnings outlook. The firm increased its EPS forecasts to $0.56 for FY2026, $2.95 for FY2028, $3.28 for FY2029 and $3.42 for FY2030, while maintaining a Buy rating. The revisions imply confidence in ACADIA’s earnings growth trajectory. HC Wainwright earnings estimate revisions
• Positive Sentiment: Citizens JMP raised its ACADIA price target to $36. The higher target provides additional upside relative to the recent trading level and reinforces the bullish tone surrounding the stock. Citizens JMP raises ACADIA price target
• Positive Sentiment: Recent results exceeded expectations. ACADIA reported quarterly EPS of $0.18 versus a $0.07 consensus estimate and revenue of $308 million versus expectations of $296.55 million. Revenue increased 16.4% year over year, supporting the view that operating momentum is improving. ACADIA reaches new 52-week high after earnings beat
• Positive Sentiment: Rising earnings estimates are supporting the stock. Zacks highlighted ACADIA among healthcare companies with strong earnings momentum and said recent estimate revisions could support further near-term gains. Zacks ACADIA earnings estimate outlook
• Neutral Sentiment: A separate Zacks analysis compares ACADIA’s year-to-date performance with Amneal Pharmaceuticals and the broader medical sector, providing performance context rather than a new company-specific catalyst. ACADIA performance comparison
• Negative Sentiment: HC Wainwright trimmed its Q4 2026 EPS estimate slightly to $0.20 from $0.21 and used a Hold rating in one related note, signaling some caution around near-term results. HC Wainwright quarterly estimate update

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Several institutional investors have recently modified their holdings of ACAD. Farther Finance Advisors LLC lifted its position in ACADIA Pharmaceuticals by 67.5% in the 4th quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 386 shares during the last quarter. Meeder Asset Management Inc. bought a new position in ACADIA Pharmaceuticals during the fourth quarter valued at approximately $26,000. Transamerica Financial Advisors LLC raised its stake in shares of ACADIA Pharmaceuticals by 304.5% during the fourth quarter. Transamerica Financial Advisors LLC now owns 1,335 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 1,005 shares in the last quarter. Federated Hermes Inc. raised its stake in shares of ACADIA Pharmaceuticals by 277.5% during the fourth quarter. Federated Hermes Inc. now owns 1,612 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 1,185 shares in the last quarter. Finally, Leonteq Securities AG bought a new stake in shares of ACADIA Pharmaceuticals in the 4th quarter worth approximately $52,000. 96.71% of the stock is currently owned by institutional investors.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.